mia542

1
WELCOME TO APPLE PHARMACEUTICALS
2
Veenat (100mg400mg)

• Veenat 100mg is a antineoplastic agents and used
  by alone regimen or together with other medicines
  for the treatment of different types of cancer or
  bone marrow conditions, the main ingredient which
  is used asimatinib . Veenat 100mg will prevents
  the development of cancer cells in the
  body. Veenat 100mg is manufactured by Natco
  Pharma Ltd with 120 capsules in a
  container. Veenat 100mg strength available is
  100mg, 100mg.

3

• DOSAGE
• Adult  
  PO  Chronic myeloid leukaemia 
  Chronic phase 
  The patients with Chronic phase the drug
  administrated 400 mg per day, given up to 600
  mg/day or 400 mg bid if needed. The patients with
  Blast crisis or accelerated phase administrated
  600 mg per day, up to 400 mg bid if required.
  Acute lymphoblastic leukaemia Dose of 600 mg per
  day with induction, consolidation or maintenance
  therapy Monotherapy in relapsed or refractory
  acute lymphoblastic leukaemia 400 mg per day up
  to 400 mg bid is administrated for Unresectable,
  metastatic GI stromal tumours 400 mg/day.
  starting with100 mg/day in patients w/ith
  FIP1L1-PDGF-a fusion kinase is given for
  Hypereosinophilic syndrome

4

• MECHANISM OF ACTION
• Imatinib is a protein-tyrosine
  kinase inhibitor which inhibits the Bcr-Abl
  tyrosine kinase, the constitutive abnormal
  tyrosine kinase created by the Philadelphia
  chromosome abnormality in chronic myeloid
  leukemia (CML).

5
Veenat 400mg

• Veenat 400mg is a antineoplastic agents and used
  by alone regimen or together with other medicines
  for the treatment of different types of cancer or
  bone marrow conditions, the main ingredient which
  is used as imatinib .
•  Veenat 400mg will prevents the development of
  cancer cells in the body. Veenat 400mg is
  manufactured by Natco Pharma Ltd with 120
  capsules in a container. Veenat 400mg strength
  available is 400mg, 100mg.

6

• DOSAGE
• Adult   PO 
  Chronic myeloid leukaemia  Chronic
  phase  The patients with
  Chronic phase the drug administrated 400 mg per
  day, given up to 600 mg/day or 400 mg bid if
  needed. The patients with Blast crisis or
  accelerated phase administrated 600 mg per day,
  up to 400 mg bid if required. Acute lymphoblastic
  leukaemia Dose of 600 mg per day with induction,
  consolidation or maintenance therapy
  Monotherapy in relapsed or refractory acute
  lymphoblastic leukaemia 400 mg per day up to 400
  mg bid is administrated for Unresectable,
  metastatic GI stromal tumours 400 mg/day.
  starting with100 mg/day in patients w/ith
  FIP1L1-PDGF-a fusion kinase is given for
  Hypereosinophilic syndrome

7

• MECHANISM OF ACTION
• Imatinib is a protein-tyrosine kinase inhibitor
  which inhibits the Bcr-Abl tyrosine kinase, the
  constitutive abnormal tyrosine kinase created by
  the Philadelphia chromosome abnormality in
  chronic myeloid leukemia (CML).
• Myelodysplastic disease 400 mg per
  day. Mastocytosis 400 mg per day. starting
  with100 mg/day if there is analog
  eosinophilia. Dermatofibrosarcoma protuberans
  400 mg bid. Veenat 400mg should be taken with
  food by oral route.

8

• Contact Details
• Phone [phone]
• Email info_at_myapplepharma.com